Reunion Neuroscience (TSX:REUN) Common Stock : C$107.27 Mil (As of Mar. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Common Stock?

Reunion Neuroscience's quarterly common stock increased from Sep. 2022 (C$107.17 Mil) to Dec. 2022 (C$107.17 Mil) and increased from Dec. 2022 (C$107.17 Mil) to Mar. 2023 (C$107.27 Mil).

Reunion Neuroscience's annual common stock increased from Mar. 2021 (C$130.78 Mil) to Mar. 2022 (C$132.11 Mil) but then declined from Mar. 2022 (C$132.11 Mil) to Mar. 2023 (C$107.27 Mil).

Reunion Neuroscience Common Stock Historical Data

The historical data trend for Reunion Neuroscience's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Common Stock Chart

Reunion Neuroscience Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Common Stock

12.78

130.78

132.11

107.27

Reunion Neuroscience Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Common Stock	Get a 7-Day Free Trial										132.11	132.11	107.17	107.17	107.27

Reunion Neuroscience Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Reunion Neuroscience (TSX:REUN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3

Website

https://www.reunionneuro.com

Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.